Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 86
Filtrar
Más filtros

Banco de datos
Tipo del documento
Intervalo de año de publicación
1.
Microvasc Res ; 139: 104260, 2022 01.
Artículo en Inglés | MEDLINE | ID: mdl-34624308

RESUMEN

OBJECTIVES: To explore whether minimally modified low-density lipoprotein (mmLDL) upregulates mesenteric arterial 5-hydroxytryptamine 1B (5-HT1B) receptor expression by activating the JAK2/STAT3 signaling pathway. METHODS: Mice were randomly divided into the following groups: the normal saline (NS), LDL, mmLDL, mmLDL+galiellactone (GL, a JAK2/STAT3 pathway inhibitor), and mmLDL+DMSO groups. The dose-response curve of mesenteric arterial ring constriction after administration of 5-carboxamidotryptamine (5-CT), an agonist of 5-HT1B, was recorded with a microvascular tensiometer. JAK2, p-JAK2, STAT3, p-STAT3, and 5-HT1B receptor protein expression levels were determined by Western blotting. 5-HT1B receptor mRNA levels were measured by RT-PCR. 5-HT1B receptor protein expression was determined by immunofluorescence. RESULTS: Injection of mmLDL into the tail vein significantly increased the contractile dose-response curve after 5-CT stimulation, as the Emax was 82.15 ±â€¯6.15% in the NS group and 171.88 ±â€¯5.78% in the mmLDL group (P < 0.01); significantly elevated 5-HT1B receptor mRNA and protein expression levels; and significantly increased p-JAK2 and p-STAT3 protein expression levels. After intraperitoneal injection of GL, the vasoconstrictive response was significantly reduced compared with that in the mmLDL group, as the Emax was decreased to 97.14 ±â€¯1.20% (P < 0.01); 5-HT1B receptor mRNA and protein expression levels were significantly reduced; STAT3 phosphorylation and p-JAK2 and p-STAT3 protein expression were not significantly changed; and 5-HT1B receptor expression was altered via inhibition of p-STAT3 binding to DNA, which suppressed transcription. CONCLUSIONS: mmLDL can upregulate 5-HT1B receptor expression in mouse mesenteric arteries by activating the JAK2/STAT3 signaling pathway.


Asunto(s)
Janus Quinasa 2/metabolismo , Lipoproteínas LDL/farmacología , Arterias Mesentéricas/efectos de los fármacos , Receptor de Serotonina 5-HT1B/metabolismo , Factor de Transcripción STAT3/metabolismo , Vasoconstricción/efectos de los fármacos , Animales , Activación Enzimática , Femenino , Masculino , Arterias Mesentéricas/enzimología , Ratones , Fosforilación , Receptor de Serotonina 5-HT1B/genética , Transducción de Señal , Regulación hacia Arriba
2.
Microvasc Res ; 127: 103923, 2020 01.
Artículo en Inglés | MEDLINE | ID: mdl-31494123

RESUMEN

Minimally modified low-density lipoprotein (mmLDL) is a risk factor for cardiovascular disease. This study was designed to investigate the effect of a Toll-like receptor 4 monoclonal antibody (TLR4 mAb) on mmLDL-induced endothelium-dependent vasodilation (EDV) impairment in mouse mesenteric arteries and to explore the underlying mechanism. Animals were divided into a normal control group, an mmLDL treatment group, and a TLR4 mAb intervention group. The serum concentrations of IL-1ß and TNF-α were detected using enzyme-linked immunosorbent assays (ELISAs). EDV function was measured using a microvascular tension tracing method. The protein levels and mRNA expression of IL-1ß and TNF-α in vascular tissue were detected using western blot analysis and reverse transcription polymerase chain reaction, respectively. TLR4 mAb improved mmLDL-induced EDV functional impairment in a dose-dependent manner. TLR4 mAb significantly upregulated KCa3.1 and KCa2.3 channel protein levels and downregulated TNF-α and IL-1ß expression. These effects were possibly associated with the competitive antagonism of TLR4 mAb on the TLR4 signaling pathway and the downstream NF-κB p65 and p38 MAPK pathways, which are activated by mmLDL. In conclusion, pretreatment with TLR4 mAb lessens mmLDL-induced EDV dysfunction and inhibits overexpression of inflammatory factors. Regulation of the TLR4 pathway, as well as its downstream NF-κB p65 and p38 MAPK pathways, may be an effective strategy for the prevention and treatment of cardiovascular diseases.


Asunto(s)
Anticuerpos Monoclonales/farmacología , Endotelio Vascular/efectos de los fármacos , Lipoproteínas LDL/farmacología , Arterias Mesentéricas/efectos de los fármacos , Receptor Toll-Like 4/antagonistas & inhibidores , Vasodilatación/efectos de los fármacos , Animales , Endotelio Vascular/inmunología , Endotelio Vascular/metabolismo , Femenino , Interleucina-1beta/sangre , Interleucina-1beta/genética , Canales de Potasio de Conductancia Intermedia Activados por el Calcio/genética , Canales de Potasio de Conductancia Intermedia Activados por el Calcio/metabolismo , Masculino , Arterias Mesentéricas/inmunología , Arterias Mesentéricas/metabolismo , Ratones Endogámicos ICR , Fosforilación , Transducción de Señal , Canales de Potasio de Pequeña Conductancia Activados por el Calcio/genética , Canales de Potasio de Pequeña Conductancia Activados por el Calcio/metabolismo , Receptor Toll-Like 4/inmunología , Receptor Toll-Like 4/metabolismo , Factor de Transcripción ReIA/metabolismo , Factor de Necrosis Tumoral alfa/sangre , Factor de Necrosis Tumoral alfa/genética , Proteínas Quinasas p38 Activadas por Mitógenos/metabolismo
3.
Microvasc Res ; 123: 42-49, 2019 05.
Artículo en Inglés | MEDLINE | ID: mdl-30367840

RESUMEN

Tetrahydroxystilbene glucoside (TSG) is the main water-soluble component in Polygonum multiflorum Thunb, and it has many cardioprotective effects. Although TSG is able to relax blood vessels, its relaxation of rat superior mesenteric arteries and the underlying mechanism of this process are not clearly understood. The aim of the present study was to use in vivo and in vitro models to investigate the arterial relaxation effect of TSG on rat superior mesenteric arteries and the mechanisms involved. We found that TSG concentration-dependently relaxed the superior mesenteric artery with or without endothelium. The vasorelaxation induced by TSG is not related to the vasodilator derived factor NO but is rather by the inhibition of COX-2 activity and decreased TXA2. We also found that the vasorelaxation induced by TSG was attenuated by 4­AP. Moreover, TSG also inhibited the contraction induced by an increase in external calcium concentration in Ca2+-free medium plus KCl (60 mM). These results suggest that TSG induces relaxation in mesenteric arterial rings through an endothelium-dependent pathway that involves the inhibition of COX-2 activity and decreased in TXA2 and through an endothelium-independent pathway via opening of a voltage-dependent K+ channel, blockade of Ca2+ influx and release of intracellular Ca2+.


Asunto(s)
Inhibidores de la Ciclooxigenasa 2/farmacología , Endotelio Vascular/efectos de los fármacos , Glucósidos/farmacología , Músculo Liso Vascular/efectos de los fármacos , Estilbenos/farmacología , Vasodilatación/efectos de los fármacos , Vasodilatadores/farmacología , Animales , Señalización del Calcio/efectos de los fármacos , Ciclooxigenasa 2/metabolismo , Relación Dosis-Respuesta a Droga , Endotelio Vascular/metabolismo , Masculino , Arteria Mesentérica Superior/efectos de los fármacos , Arteria Mesentérica Superior/metabolismo , Ratones Endogámicos C57BL , Músculo Liso Vascular/metabolismo , Canales de Potasio con Entrada de Voltaje/agonistas , Canales de Potasio con Entrada de Voltaje/metabolismo , Ratas Sprague-Dawley , Tromboxano A2/metabolismo
4.
Biol Pharm Bull ; 42(5): 703-711, 2019.
Artículo en Inglés | MEDLINE | ID: mdl-31061312

RESUMEN

Cigarette smoke is a well-known strong risk factor for inducing airway hyperreactivity (AHR), but the underlying molecular mechanisms are not fully understood. In the present study, mouse in-vivo and in-vitro models were used to study effects of dimethyl sulfoxide (DMSO)-extracted cigarette smoke particles (DSP) on the airway, and to explore the underlying molecular mechanisms that are involved in DSP-induced AHR. In mouse in-vivo model, DSP (0.75, 1.5 or 3 µL/mL) was administered intranasally daily for 7 d. At the end of this period, lung functions were measured with flexiVent™. The results showed that the mice exhibited AHR in a dose-dependent manner following methacholine inhalation in vivo. In mouse in-vitro organ culture model, exposure of mouse tracheal segments to DSP (0.1 µL/mL) with or without the following pharmacological inhibitors: specific c-Jun-N-terminal kinase (JNK) inhibitor SP600125 (10 µM) or the anti-inflammatory drug dexamethasone (1 µM). DSP-induced bradykinin receptor-mediated airway contraction with increased mRNA and protein expressions for bradykinin B1 and B2 receptors could be significantly reduced by SP600125 or dexamethasone. In conclusion, the present study demonstrates that DSP could induce AHR in vivo and in vitro. In addition to this, the upregulation of bradykinin receptors in airway is most likely one of the underlying molecular mechanisms involved.


Asunto(s)
Hiperreactividad Bronquial/inducido químicamente , Nicotiana/efectos adversos , Humo/efectos adversos , Animales , Antracenos/farmacología , Antiinflamatorios/farmacología , Dexametasona/farmacología , Dimetilsulfóxido/química , Proteínas Quinasas JNK Activadas por Mitógenos/fisiología , Masculino , Ratones Endogámicos BALB C , Receptor de Bradiquinina B1/fisiología , Receptor de Bradiquinina B2/fisiología , Solventes/química , Tráquea/efectos de los fármacos , Tráquea/fisiología
5.
Cancer Cell Int ; 18: 195, 2018.
Artículo en Inglés | MEDLINE | ID: mdl-30524203

RESUMEN

BACKGROUND: MicroRNAs play crucial roles in tumorigenesis and tumor progression. miR-770 has been reported to be downregulated in several cancers and affects cancer cell proliferation, apoptosis, metastasis and drug resistance. However, the role and underlying molecular mechanism of miR-770 in human glioma remain unknown and need to be further elucidated. METHODS: The expression of miR-770 in glioma tissues and cell lines was measured by quantitative real-time PCR (qRT-PCR) to explore the association of miR-770 expression with clinicopathological characteristics. The expression of CDK8 was detected by qRT-PCR and Western blotting in glioma tissues. A target prediction program and a dual-luciferase reporter assay were used to confirm that CDK8 is a target gene of miR-770. MTT and cell counting assays were used to assess the effect of miR-770 on glioma cell proliferation. The cell cycle distribution and apoptosis were examined by flow cytometry. CDK8 siRNA and overexpression were used to further confirm the function of the target gene. RESULTS: We demonstrated that miR-770 expression was downregulated in human glioma tissues and cell lines. The overexpression of miR-770 inhibited glioma cell proliferation and cell cycle G1-S transition and induced apoptosis. The inhibition of miR-770 facilitated cell proliferation and G1-S transition and suppressed apoptosis. miR-770 expression was inversely correlated with CDK8 expression in glioma tissues. CDK8 was confirmed to be a direct target of miR-770 by using a luciferase reporter assay. The overexpression of miR-770 decreased CDK8 expression at both the mRNA and protein levels, and the suppression of miR-770 increased CDK8 expression. Importantly, CDK8 silencing recapitulated the cellular and molecular effects observed upon miR-770 overexpression, and CDK8 overexpression eliminated the effects of miR-770 overexpression on glioma cells. Moreover, both exogenous expression of miR-770 and silencing of CDK8 resulted in suppression of the Wnt/ß-catenin signaling pathway. CONCLUSIONS: Our study demonstrates that miR-770 inhibits glioma cell proliferation and G1-S transition and induces apoptosis through suppression of the Wnt/ß-catenin signaling pathway by targeting CDK8. These findings suggest that miR-770 plays a significant role in glioma progression and serves as a potential therapeutic target for glioma.

6.
J Vasc Res ; 53(1-2): 58-71, 2016.
Artículo en Inglés | MEDLINE | ID: mdl-27577886

RESUMEN

Minimally modified low-density lipoprotein (mmLDL) is a well-known risk factor for cardiovascular diseases. The present study was designed to investigate the role of mmLDL in the endothelium-dependent relaxation of mouse mesenteric arteries. A sensitive myograph system was employed to examine the endothelial function of mesenteric arteries. mRNA and protein expression levels were determined using real-time PCR and Western blotting, respectively. The ultramicrostructure of mesenteric vascular beds was investigated using a transmission electron microscope. The results showed that mmLDL significantly impaired the acetylcholine-induced (3 × 10-10 to 1 × 10-4M) endothelium-dependent relaxation of mouse mesenteric arteries with markedly reduced pIC50 (p < 0.05) and Rmax values (p < 0.001). In addition, mmLDL increased the levels of superoxide production and nitrotyrosine concentration and impaired the endothelial microstructure with decreased KCa3.1 and KCa2.3 expression. In conclusion, mmLDL increases superoxide and nitrotyrosine levels, damages endothelial microstructure with decreased KCa3.1 and KCa2.3 expression, and ultimately attenuates relaxation mediated by nitric oxide- and endothelium-derived hyperpolarizing factor.


Asunto(s)
Endotelio Vascular/efectos de los fármacos , Lipoproteínas LDL/farmacología , Arterias Mesentéricas/efectos de los fármacos , Vasodilatación/efectos de los fármacos , Animales , Factores Biológicos/metabolismo , Relación Dosis-Respuesta a Droga , Endotelio Vascular/metabolismo , Endotelio Vascular/ultraestructura , Regulación de la Expresión Génica , Técnicas In Vitro , Canales de Potasio de Conductancia Intermedia Activados por el Calcio/metabolismo , Masculino , Arterias Mesentéricas/metabolismo , Arterias Mesentéricas/ultraestructura , Ratones Endogámicos ICR , Óxido Nítrico/metabolismo , Canales de Potasio de Pequeña Conductancia Activados por el Calcio/metabolismo , Superóxidos/metabolismo , Factores de Tiempo , Tirosina/análogos & derivados , Tirosina/metabolismo , Vasoconstrictores/farmacología , Vasodilatadores/farmacología
7.
Eur J Pharmacol ; 972: 176543, 2024 Jun 05.
Artículo en Inglés | MEDLINE | ID: mdl-38582274

RESUMEN

Cyclosporin A, an immunosuppressive agent, is extensively utilized for the prevention of transplant rejection and treat autoimmune disease in the clinic, despite its association with a high risk of hypertension development among patients. Resveratrol is a kind of non-flavonoid phenolic compound that widely exists in many plants. The aim of the present study was to investigate the mechanism by which resveratrol ameliorates cyclosporin A-induced hypertension. The arterial rings of the mesentery were incubated with cyclosporin A and resveratrol in vitro. Rats were administered cyclosporin A and/or resveratrol for 3 weeks in vivo. Blood pressure was measured via the tail arteries. Vasoconstriction curves were recorded using a sensitive myograph. The protein expression was evaluated through Western blotting. This study demonstrated that resveratrol mitigated the cyclosporin A-induced increase in blood pressure in rats. Furthermore, resveratrol markedly inhibited the cyclosporin A-induced upregulation of thromboxane A2 receptor-mediated vasoconstriction in the rat mesenteric artery both in vitro and in vivo. Moreover, resveratrol activated AMPK/SIRT1 and inhibited the MAPK/NF-κB signaling pathway. In conclusion, resveratrol restored the cyclosporin A-induced upregulation of the thromboxane A2 receptor and hypertension via the AMPK/SIRT1 and MAPK/NF-κB pathways in rats.


Asunto(s)
Proteínas Quinasas Activadas por AMP , Ciclosporina , Hipertensión , Arterias Mesentéricas , FN-kappa B , Ratas Sprague-Dawley , Resveratrol , Sirtuina 1 , Regulación hacia Arriba , Animales , Resveratrol/farmacología , Ciclosporina/farmacología , Sirtuina 1/metabolismo , Arterias Mesentéricas/efectos de los fármacos , Arterias Mesentéricas/metabolismo , Hipertensión/tratamiento farmacológico , Hipertensión/metabolismo , Hipertensión/fisiopatología , Masculino , FN-kappa B/metabolismo , Regulación hacia Arriba/efectos de los fármacos , Ratas , Proteínas Quinasas Activadas por AMP/metabolismo , Vasoconstricción/efectos de los fármacos , Presión Sanguínea/efectos de los fármacos , Transducción de Señal/efectos de los fármacos , Proteínas Quinasas Activadas por Mitógenos/metabolismo
8.
Pharmacol Res ; 71: 9-18, 2013 May.
Artículo en Inglés | MEDLINE | ID: mdl-23428345

RESUMEN

Airway hyperreactivity (AHR) is a major feature of asthmatic and inflammatory airways. Cigarette smoke exposure, and bacterial and viral infections are well-known environmental risk factors for AHR, but knowledge about the underlying molecular mechanisms on how these risk factors lead to the development of AHR is limited. Activation of intracellular mitogen-activated protein kinase (MAPK)/nuclear factor-kappa B (NF-κB) and their related signal pathways including protein kinase C (PKC), phosphoinositide 3-kinase (PI3K) and protein kinase A (PKA) signaling pathways may result in airway kinin receptor upregulation, which is suggested to play an important role in the development of AHR. Environmental risk factors trigger the production of pro-inflammatory mediators such as tumor necrosis factor-α (TNF-α) and interleukins (ILs) that activate intracellular MAPK- and NF-κB-dependent inflammatory pathways, which subsequently lead to AHR via kinin receptor upregulation. Blockage of intracellular MAPK/NF-κB signaling prevents kinin B1 and B2 receptor expression in the airways, resulting in a decrease in the response to bradykinin (kinin B2 receptor agonist) and des-Arg9-bradykinin (kinin B1 receptor agonist). This suggests that MAPK- and NF-κB-dependent kinin receptor upregulation can provide a novel option for treatment of AHR in asthmatic as well as in other inflammatory airway diseases.


Asunto(s)
Asma/inmunología , Mediadores de Inflamación/inmunología , Proteínas Quinasas Activadas por Mitógenos/inmunología , FN-kappa B/inmunología , Proteínas Serina-Treonina Quinasas/inmunología , Receptor de Bradiquinina B1/inmunología , Receptor de Bradiquinina B2/inmunología , Animales , Asma/tratamiento farmacológico , Asma/genética , Humanos , Cininas/inmunología , Terapia Molecular Dirigida , Receptor de Bradiquinina B1/genética , Receptor de Bradiquinina B2/genética , Transducción de Señal , Regulación hacia Arriba , Quinasa de Factor Nuclear kappa B
9.
Mediators Inflamm ; 2013: 656570, 2013.
Artículo en Inglés | MEDLINE | ID: mdl-23861561

RESUMEN

Minimally modified low-density lipoprotein (mmLDL) is a risk factor for cardiovascular disease. The present study investigated the effects of mmLDL on the expression of endothelin type A (ET(A)) receptors in coronary arteries. Rat coronary arteries were organ-cultured for 24 h. The contractile responses were recorded using a myographic system. ET(A) receptor mRNA and protein expressions were determined using real-time PCR and western blotting, respectively. The results showed that organ-culturing in the presence of mmLDL enhanced the arterial contractility mediated by the ET(A) receptor in a concentration-dependent and time-dependent manner. Culturing with mmLDL (10 µ g/mL) for 24 h shifted the concentration-contractile curves toward the left significantly with increased E(max) of 228% ± 20% from control of 100% ± 10% and significantly increased ET(A) receptor mRNA and protein levels. Inhibition of the protein kinase C, extracellular signal-related kinases 1 and 2 (ERK1/2), or NF- κ B activities significantly attenuated the effects of mmLDL. The c-Jun N-terminal kinase inhibitor or the p38 pathway inhibitor, however, had no such effects. The results indicate that mmLDL upregulates the ETA receptors in rat coronary arterial smooth muscle cells mainly via activating protein kinase C, ERK1/2, and the downstream transcriptional factor, NF- κ B.


Asunto(s)
Lipoproteínas LDL/metabolismo , Miocitos del Músculo Liso/citología , Receptor de Endotelina A/metabolismo , Regulación hacia Arriba , Animales , Aterosclerosis/metabolismo , Vasos Coronarios/metabolismo , Vasos Coronarios/patología , Endotelina-1/metabolismo , Quinasas MAP Reguladas por Señal Extracelular/metabolismo , Inflamación , FN-kappa B/metabolismo , Técnicas de Cultivo de Órganos , Proteína Quinasa C/metabolismo , Ratas , Ratas Sprague-Dawley , Reacción en Cadena en Tiempo Real de la Polimerasa , Transducción de Señal , Proteínas Quinasas p38 Activadas por Mitógenos/metabolismo
10.
Thorax ; 67(10): 908-13, 2012 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-22550083

RESUMEN

BACKGROUND: Exposure to cigarette smoke (CS) is associated with increased risk of pneumococcal infection. The mechanism for this association is unknown. We recently reported that the particulate matter from urban air simulates platelet-activating factor receptor (PAFR)-dependent adhesion of pneumococci to airway cells. We therefore sought to determine whether CS stimulates pneumococcal adhesion to airway cells. METHODS: Human alveolar (A549), bronchial (BEAS2-B), and primary bronchial epithelial cells (HBEpC) were exposed to CS extract (CSE), and adhesion of Streptococcus pneumoniae determined. The role of PAFR in mediating adhesion was determined using a blocker (CV-3988). PAFR transcript level was assessed by quantitative real-time PCR, and PAFR expression by flow cytometry. Lung PAFR transcript level was assessed in mice exposed to CS, and bronchial epithelial PAFR expression assessed in active-smokers by immunostaining. RESULTS: In A549 cells, CSE 1% increased pneumococcal adhesion (p<0.05 vs control), PAFR transcript level (p<0.01), and PAFR expression (p<0.01). Pneumococcal adhesion to A549 cells was attenuated by CV-3988 (p<0.001). CSE 1% stimulated pneumococcal adhesion to BEAS2-B cells and HBEpC (p<0.01 vs control). CSE 1% increased PAFR expression in BEAS2-B (p<0.01), and in HBEpC (p<0.05). Lung PAFR transcript level was increased in mice exposed to CS in vivo (p<0.05 vs room air). Active smokers (n=16) had an increased percentage of bronchial epithelium with PAFR-positive cells (p<0.05 vs never smokers, n=11). CONCLUSION: CSE stimulates PAFR-dependent pneumococcal adhesion to lower airway epithelial cells. We found evidence that CS increases bronchial PAFR in vivo.


Asunto(s)
Adhesión Bacteriana/efectos de los fármacos , Adhesión Bacteriana/fisiología , Glicoproteínas de Membrana Plaquetaria/metabolismo , Infecciones Neumocócicas/etiología , Receptores Acoplados a Proteínas G/metabolismo , Sistema Respiratorio/citología , Fumar/metabolismo , Contaminación por Humo de Tabaco/efectos adversos , Animales , Línea Celular , Citometría de Flujo , Humanos , Técnicas In Vitro , Ratones , Material Particulado/metabolismo , Material Particulado/farmacología , Reacción en Cadena en Tiempo Real de la Polimerasa , Sistema Respiratorio/efectos de los fármacos , Sistema Respiratorio/microbiología , Estadísticas no Paramétricas , Streptococcus pneumoniae/metabolismo
11.
Microvasc Res ; 83(2): 178-84, 2012 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-22198335

RESUMEN

Minimally modified low density lipoprotein (mmLDL) is a well-known risk factor for cerebral vascular diseases and upregulation of endothelin type B (ET(B)) receptors plays key roles in the pathogenesis. The present study was designed to examine if mmLDL upregulated endothelin ET(B) receptors in basilar artery and its possible intracellular signaling molecular mechanisms. Rat basilar arteries were cultured for 24h in the presence of mmLDL with specific inhibitors. The artery contractile responses and receptor expressions of mRNA and protein were investigated using myograph system, real-time PCR and Western blot techniques, respectively. Results showed that ET(B) receptor agonist, sarafotoxin 6c induced a weak contraction in fresh basilar artery segments. After organ culture the contraction curve mediated by ET(B) receptor was shifted towards the left with an increased E(max) of 88 ± 6%. The mmLDL 10 µg/mL further shifted the concentration-contractile curves towards the left with an increased E(max) of 116 ± 12%. The organ culture significantly increased ET(B) receptor mRNA and protein levels from fresh arteries, which was further enhanced by mmLDL. The staurosporine (PKC inhibitor), both SB386023 and U0126 (extracellular signal related kinases 1 and 2 inhibitor), and wedelolactone (NF-κB inhibitor) almost totally abolished organ culture-increased and mmLDL-increased contraction and expressions of endothelin ET(B) receptor. SP600125 (C-jun terminal kinase inhibitor) and SB203580 (p38 inhibitor) attenuated both organ cultured-induced and mmLDL-induced upregulation of endothelin ET(B) receptors. In conclusion, mmLDL upregulates ET(B) receptors of cerebral basilar artery via the PKC, MAPK and NF-κB signal pathways.


Asunto(s)
Arteria Basilar/metabolismo , Lipoproteínas LDL/metabolismo , Receptor de Endotelina B/metabolismo , Vasoconstricción , Animales , Arteria Basilar/efectos de los fármacos , Western Blotting , Relación Dosis-Respuesta a Droga , Proteínas Quinasas JNK Activadas por Mitógenos/antagonistas & inhibidores , Proteínas Quinasas JNK Activadas por Mitógenos/metabolismo , Proteína Quinasa 1 Activada por Mitógenos/antagonistas & inhibidores , Proteína Quinasa 1 Activada por Mitógenos/metabolismo , Proteína Quinasa 3 Activada por Mitógenos/antagonistas & inhibidores , Proteína Quinasa 3 Activada por Mitógenos/metabolismo , Miografía , FN-kappa B/antagonistas & inhibidores , FN-kappa B/metabolismo , Proteína Quinasa C/antagonistas & inhibidores , Proteína Quinasa C/metabolismo , Inhibidores de Proteínas Quinasas/farmacología , ARN Mensajero/metabolismo , Ratas , Ratas Sprague-Dawley , Reacción en Cadena en Tiempo Real de la Polimerasa , Receptor de Endotelina B/agonistas , Receptor de Endotelina B/genética , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Transducción de Señal , Factores de Tiempo , Técnicas de Cultivo de Tejidos , Regulación hacia Arriba , Vasoconstricción/efectos de los fármacos , Vasoconstrictores/farmacología , Proteínas Quinasas p38 Activadas por Mitógenos/antagonistas & inhibidores , Proteínas Quinasas p38 Activadas por Mitógenos/metabolismo
12.
Int Immunol ; 23(7): 443-51, 2011 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-21677048

RESUMEN

Tumor necrosis factor-α (TNF-α) has been implicated in the pathogenesis of asthma, and neutralization of TNF-α is an effective therapy for inflammatory diseases. The present study tested the idea that a TNF-α antibody, infliximab, may be useful in the management of asthma. E3 rats were immunized with ovalbumin (OVA)/alum and received infliximab intra-peritoneally. Two weeks later, OVA-PBS was instilled intranasally daily for 7 days. Bronchoalveolar lavage fluids (BALFs), serum and lung homogenates were collected for analysis of cells and inflammatory mediators. Contractile responses of lobar-bronchus segments to agonists were functionally tested. Pulmonary tissues were investigated using histological examination. The results showed that the sensitized 'model E3 rats' exhibited an increase in the total amount of inflammatory cells, primarily eosinophils, in BALF and pulmonary tissue, as well as epithelial damage. Serum levels of IgE increased and so did the levels of nitric oxide, inducible nitric oxide synthase, TNF-α and IL-4, IL-5 and IL-13 in lung homogenate and serum. Furthermore, the contractile responses in bronchi induced by endothelin-1, sarafotoxin 6c and bradykinin increased and isoprenaline-induced relaxations decreased. All these changes induced by the sensitization procedure were reduced by the infliximab treatment. The results suggest that infliximab prevents the development of local airway inflammation and antagonizes changes of the bronchial smooth muscle receptor phenotype, thereby blocking the development of airway smooth muscle hyperreactivity of asthmatic rats.


Asunto(s)
Antiasmáticos/farmacología , Antiasmáticos/uso terapéutico , Anticuerpos Monoclonales/farmacología , Anticuerpos Monoclonales/uso terapéutico , Asma/tratamiento farmacológico , Inflamación/inmunología , Músculo Liso/efectos de los fármacos , Animales , Arginasa/metabolismo , Asma/sangre , Asma/patología , Líquido del Lavado Bronquioalveolar/inmunología , Citocinas/sangre , Modelos Animales de Enfermedad , Eosinófilos/efectos de los fármacos , Eosinófilos/inmunología , Eosinófilos/patología , Inmunoglobulina E/sangre , Inflamación/metabolismo , Inflamación/patología , Infliximab , Pulmón/efectos de los fármacos , Pulmón/inmunología , Pulmón/metabolismo , Pulmón/patología , Masculino , Músculo Liso/inmunología , Óxido Nítrico/sangre , Óxido Nítrico Sintasa/metabolismo , Ratas
13.
Eur J Pharmacol ; 926: 175034, 2022 Jul 05.
Artículo en Inglés | MEDLINE | ID: mdl-35588871

RESUMEN

Cyclosporin A (CsA) is an immunosuppressant used in transplantation patients and inflammatory diseases. CsA-induced local vasoconstriction can lead to serious side effects including nephrotoxicity and hypertension. However, the underlying mechanisms are not fully understood. Mesenteric artery rings of rats were cultured with CsA and specific inhibitors for mitogen-activating protein kinases (MAPK) and nuclear factor-κB (NF-κB) signaling pathways. A sensitive myograph recorded thromboxane (TP) receptor-mediated vasoconstriction. Protein levels of key signaling molecules were assessed by Western blotting. The results show that CsA up-regulated the TP receptor expression with the enhanced vasoconstriction in a dose- and time-dependent manner. Furthermore, the blockage of MAPKs or NF-κB activation markedly attenuated CsA-enhanced vasoconstriction and the TP receptor protein expression. Rats subcutaneously injected with CsA for three weeks showed increased blood pressure in vivo and increased contractile responses to a TP agonist ex vivo. CsA also enhanced TP receptor, as well as p-ERK1/2, p-p38, p- IκBα, p-NF-κB P65 protein levels and decreased IκBα protein expression, demonstrating that CsA induced TP receptor enhanced-vasoconstriction via activation of MAPK and NF-κB pathways. In conclusion, CsA up-regulated the expression of TP receptors via activation of MAPK and NF-κB pathways. The results may provide novel options for prevention of CsA-associated hypertension.


Asunto(s)
Ciclosporina , Hipertensión , FN-kappa B , Receptores de Tromboxano A2 y Prostaglandina H2 , Animales , Ciclosporina/farmacología , Humanos , Arterias Mesentéricas/metabolismo , Proteínas Quinasas Activadas por Mitógenos/metabolismo , Mitógenos , Inhibidor NF-kappaB alfa , FN-kappa B/metabolismo , Ratas , Receptores de Tromboxanos , Receptores de Tromboxano A2 y Prostaglandina H2/efectos de los fármacos , Receptores de Tromboxano A2 y Prostaglandina H2/metabolismo , Tromboxanos , Proteínas Quinasas p38 Activadas por Mitógenos/metabolismo
14.
Chem Biol Interact ; 368: 110203, 2022 Dec 01.
Artículo en Inglés | MEDLINE | ID: mdl-36183783

RESUMEN

Smoking is a well-known risk factor for cardiovascular diseases. However, the mechanisms behind how smoking leads to vasospasm are not fully elucidated. Endothelin receptors are involved in the pathogenesis of cardiovascular diseases. This study examined whether cigarette smoke could induce up-regulation of vascular endothelin receptors through AMPK-SIRT1 and MAPK pathways. The results show that DMSO-soluble smoking particles (DSP) up-regulated the protein expressions of endothelin receptors and the contractile responses. Furthermore, the inhibition of MAPK or activation of AMPK-SIRT1 markedly attenuated DSP-enhanced vasoconstriction and the protein expression of endothelin receptors. The in vivo study showed that cigarette smoke increased the blood pressure of the rats and down-regulated p-AMPKα, SIRT1, and up-regulated endothelin receptors, p-ERK1/2, and p-P38 protein expressions. However, treatment with resveratrol attenuated vasoconstriction, endothelin receptor proteins expression, and blood pressure in vivo. In conclusion, this suggests that cigarette smoke up-regulates the vascular endothelin receptors through AMPK-SIRT1 and MAPK pathways.


Asunto(s)
Enfermedades Cardiovasculares , Receptores de Endotelina , Ratas , Animales , Receptores de Endotelina/metabolismo , Sirtuina 1 , Dimetilsulfóxido , Proteínas Quinasas Activadas por AMP , Ratas Sprague-Dawley , Nicotiana/metabolismo , Fumar
15.
BMC Neurosci ; 12: 109, 2011 Nov 01.
Artículo en Inglés | MEDLINE | ID: mdl-22044770

RESUMEN

BACKGROUND: Cigarette smoking enhances the risk of stroke. However, the underlying molecular mechanisms are largely unknown. The present study established an in vivo rat secondhand cigarette smoking (SHS) model and examined the hypothesis that SHS upregulates endothelin receptors with increased cerebrovascular contraction via the Raf/extracellular signal-regulated kinase (ERK)/mitogen-activated protein kinases (MAPK) pathway. RESULTS: Rats were exposed to SHS for up to 8 weeks. The cerebral artery vasoconstriction was recorded by a sensitive myograph. The mRNA and protein expressions for endothelin receptors in cerebral arteries were studied by real-time PCR and Western blot. Compared to fresh air exposed rats, cerebral arteries from SHS rats exhibited stronger contractile responses (P < 0.05) mediated by endothelin type A (ETA) receptors. The expressions of mRNA and protein for ETA receptors in the cerebral arteries from SHS rats were higher (P < 0.05) than that in control. SHS did not affect endothelin type B (ETB) receptor-mediated contractions, mRNA or protein levels. The results suggest that SHS upregulates ETA, but not ETB receptors in vivo. After SHS exposure, the mRNA levels of Raf-1 and ERK1/2, the protein expression of phosphorylated (p)-Raf-1 and p-ERK1/2 were increased (P < 0.05). Raf-1 inhibitor, GW5074 suppressed the enhanced ETA receptor-mediated contraction, mRNA and protein levels induced by SHS. In addition, GW5074 inhibited the SHS-caused increased mRNA and phosphorylated protein levels of Raf-1 and ERK1/2, suggesting that SHS induces activation of the Raf/ERK/MAPK pathway. CONCLUSIONS: SHS upregulates cerebrovascular ETA receptors via the Raf/ERK/MAPK pathway, which provides novel understanding of mechanisms involved in SHS-associated stroke.


Asunto(s)
Circulación Cerebrovascular/fisiología , Sistema de Señalización de MAP Quinasas/fisiología , Receptor de Endotelina A/biosíntesis , Accidente Cerebrovascular/enzimología , Accidente Cerebrovascular/etiología , Contaminación por Humo de Tabaco/efectos adversos , Regulación hacia Arriba/fisiología , Quinasas raf/fisiología , Animales , Masculino , Ratas , Ratas Sprague-Dawley , Receptor de Endotelina A/genética , Accidente Cerebrovascular/metabolismo , Quinasas raf/antagonistas & inhibidores , Quinasas raf/genética
16.
Toxicol Appl Pharmacol ; 252(2): 138-49, 2011 Apr 15.
Artículo en Inglés | MEDLINE | ID: mdl-21316381

RESUMEN

The cardiovascular risk for users of use of Swedish snus/American snuff (moist tobacco) has been debated for a long time. The present study was designed to examine the effects of water- or lipid-soluble (DMSO-soluble) snus and nicotine, the most important substance in tobacco, on the expression of vasocontractile G-protein coupled receptors (GPCR), such as endothelin ET(B), serotonin 5-HT(1B), and thromboxane A(2) TP receptors, in rat cerebral arteries. Studies show that these vasocontractile GPCR show alterations by lipid-soluble cigarette smoke particles via activation of mitogen-activated protein kinases (MAPK). However, the effects of moist tobacco on the expression of GPCR are less studied. Rat middle cerebral arteries were isolated and organ cultured in serum-free medium for 24h in the presence of water-soluble snus (WSS), DMSO-soluble snus (DSS), or nicotine. The dose of snus and nicotine was kept at plasma level of snus users (25ng nicotine/ml). A high dose (250ng nicotine/ml) was also included due to the previous results showing alteration in the GPCR expression by nicotine at this concentration. Contractile responses to the ET(B) receptor agonist sarafotoxin 6c, 5-HT(1B) receptor agonist 5-carboxamidotryptamine, and TP receptor agonist U46619 were investigated by a sensitive myograph. The expression of ET(B), 5-HT(1B), and TP receptors was studied at mRNA and protein levels using quantitative real-time PCR and immunohistochemistry, respectively. Organ culture with WSS or DSS (25ng nicotine/ml) lowered the 5-HT(1B) receptor-mediated contraction. Furthermore, DSS shifted the TP receptor-mediated contraction curve left-wards with a stronger contraction. High dose of nicotine (250ng nicotine/ml) increased the ET(B) receptor-mediated contraction. The combined 5-HT(1B) and 5-HT(2A) receptor-mediated contraction was increased, and both the 5-CT and TxA2 induced contractions were left-ward shifted by WSS, DSS, or nicotine (250ng nicotine/ml). Only the DSS group showed that the increase of 5-HT(1B) receptor-mediated contraction occurred at the transcriptional level, demonstrated by an increased mRNA expression for the receptor. Thus, snus and nicotine alter the GPCR expression in the cerebral arteries, which may be involved in cerebral vascular disease.


Asunto(s)
Arterias Cerebrales/efectos de los fármacos , Regulación de la Expresión Génica , Nicotina/toxicidad , Receptores Acoplados a Proteínas G/biosíntesis , Tabaco sin Humo/toxicidad , Vasoconstricción/efectos de los fármacos , Animales , Arterias Cerebrales/metabolismo , Relación Dosis-Respuesta a Droga , Humedad , Masculino , Técnicas de Cultivo de Órganos , Ratas , Ratas Sprague-Dawley , Vasoconstricción/fisiología
17.
Cephalalgia ; 31(1): 95-105, 2011 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-20851839

RESUMEN

BACKGROUND AND OBJECTIVE: Clinical and experimental studies have revealed a central role of calcitonin gene-related peptide (CGRP) in primary headaches. The role of extracellular signal-regulated kinase 1 and 2 (ERK1/2) in neuronal and glial cell expression of CGRP- immunoreactivity (-ir) in rat trigeminal ganglia was studied with an organ culture method. EXPERIMENTAL PROCEDURES: Sections of adult rat trigeminal ganglia were cultured for up to 48 hours, examined with immunohistochemistry and quantitative real-time polymerase chain reaction (PCR) assay. Specific antibodies against CGRP, phosphorylated ERK1/2 (pERK1/2), total ERK1/2 (tERK1/2), phosphorylated p38 (pp38), phosphorylated C-Jun-N-terminal protein kinase (pJNK), pro-calcitonin (pro-CT), CGRP receptor activity modifying protein 1 (RAMP1), glutamine synthetase (GS) and pro-CT were used. To explore molecular mechanisms involved in the organ culture-induced CGRP-ir in neurons and glial cells, the effects of the MEK/ERK1/2 inhibitor U0126, its inactive analogue U0124, the p38 inhibitor SB203580 and the JNK inhibitor SP600125 were studied. RESULTS: In fresh ganglia, small- and medium-sized neurons were CGRP-ir while some larger neurons displayed RAMP1-ir. Glial cells were negative to both. After organ culture, neurons showed enhanced CGRP- and RAMP1-ir. In addition, some glial cells were RAMP1- and CGRP-ir. Isolated glial cells and neurons were found to contain CGRP mRNA, and showed pro-CT-ir, suggestive of local formation of CGRP. Neurons and glial cells showed enhanced pERK1/2-ir already after two hours of organ culture and this remained elevated for 48 hours. There was transient pJNK-ir in neurons at two hours, while pp38-ir was not altered. U0126 reduced the enhanced pERK1/2-ir, while U0124 had no such effect; the CGRP-ir in neurons and glial cells was reduced at 48 hours and in parallel the CGRP mRNA expression was lower at 24 hours. CONCLUSION: We suggest that in conditions of elevated CGRP expression, inhibition of ERK1/2 might be an option for novel treatment.


Asunto(s)
Péptido Relacionado con Gen de Calcitonina/biosíntesis , Proteína Quinasa 3 Activada por Mitógenos/biosíntesis , Transducción de Señal/fisiología , Ganglio del Trigémino/metabolismo , Animales , Activación Enzimática/fisiología , Inhibidores Enzimáticos/farmacología , Procesamiento de Imagen Asistido por Computador , Inmunohistoquímica , Masculino , Proteína Quinasa 1 Activada por Mitógenos/biosíntesis , Neuroglía/metabolismo , Neuronas/metabolismo , Técnicas de Cultivo de Órganos , Ratas , Ratas Sprague-Dawley , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Transducción de Señal/efectos de los fármacos , Ganglio del Trigémino/citología
18.
Yao Xue Xue Bao ; 46(12): 1451-6, 2011 Dec.
Artículo en Zh | MEDLINE | ID: mdl-22375417

RESUMEN

The Chinese herbal medicine Tianma (Gastrodia elata) has been used for treating and preventing primary headache over thousands of years, but the exact pharmacological mechanism of the main bioactive ingredient gastrodin remains unclear. In present study, the effects of gastrodin on calcitonin gene-related peptide (CGRP) and phosphorylated extracellular signal-regulated kinase1/2 (pERK1/2) expression were observed in rat trigeminal ganglion (TG) after in vitro organ culture to explore the underlying intracellular mechanism of gastrodin on primary vascular-associated headache. CGRP-immunoreactivity (CGRP-ir) positive neurons count, positive area, mean optical density and integrated optical density by means of immunohistochemistry stain were compared at different concentrations of gastrodin, which was separately co-incubated with DMEM in SD rat TG for 24 hours. Only at 5 or 10 mmol L(-1) concentration, gastrodin demonstrated significantly concentration-dependent reduction of CGRP-ir (+) expression and its action closed to 1.2 mmol L(-1) sumatriptan succinate. While at 2.5, 20, and 40 mmol L(-1) concentration, gastrodin did not show remarkable effects on CGRP-ir (+) expression. The optimal concentration of gastrodin (5 and 10 mmol L(-1)) similarly inhibited CGRP-mRNA expression level separately compared with 1.2 mmol L(-1) sumatriptan succinate and 10 micromol L(-1) flunarizine hydrochloride, which was quantitatively analyzed by real-time PCR (RT-PCR). pERK1/2 level was examined by Western blotting after co-cultured with optimal concentration of gastrodin and effective specific ERK1/2 pathway inhibitors PD98059, U0126. The result indicated that gastrodin significantly reduced pERK1/2 protein actions similarly to ERK1/2 pathway specific blockade. It suggests ERK1/2 signaling transduction pathway may be involved in gastrodin intracellular mechanism. This study indicates gastrodin (5 and 10 mmol L(-1)) can remarkably reduce CGRP-ir (+) neuron, CGRP-mRNA and pERK1/2 expression level in cultured rat TG, with its actions similar to the effective concentration of sumatriptan succinate, flunarizine hydrochloride and specific ERK1/2 pathway blocker. The intracellular signaling transduction ERK1/2 pathway may be involved in the gastrodin reducing CGRP up-regulation in rat TG after organ culture.


Asunto(s)
Alcoholes Bencílicos/farmacología , Péptido Relacionado con Gen de Calcitonina/metabolismo , Glucósidos/farmacología , Sistema de Señalización de MAP Quinasas/efectos de los fármacos , Ganglio del Trigémino/metabolismo , Animales , Alcoholes Bencílicos/administración & dosificación , Alcoholes Bencílicos/aislamiento & purificación , Butadienos/farmacología , Péptido Relacionado con Gen de Calcitonina/genética , Relación Dosis-Respuesta a Droga , Flavonoides/farmacología , Flunarizina/farmacología , Gastrodia/química , Glucósidos/administración & dosificación , Glucósidos/aislamiento & purificación , Masculino , Proteína Quinasa 1 Activada por Mitógenos/antagonistas & inhibidores , Proteína Quinasa 1 Activada por Mitógenos/metabolismo , Proteína Quinasa 3 Activada por Mitógenos/antagonistas & inhibidores , Proteína Quinasa 3 Activada por Mitógenos/metabolismo , Nitrilos/farmacología , Técnicas de Cultivo de Órganos , Plantas Medicinales/química , ARN Mensajero , Ratas , Ratas Sprague-Dawley , Sumatriptán/farmacología , Vasoconstrictores/farmacología , Vasodilatadores/farmacología
19.
Toxicol Appl Pharmacol ; 249(1): 25-32, 2010 Nov 15.
Artículo en Inglés | MEDLINE | ID: mdl-20716444

RESUMEN

Cigarette smoke exposure increases the risk of stroke. However, the underlying molecular mechanisms are poorly understood. Endothelin system plays key roles in the pathogenesis of stroke. The present study was designed to examine if lipid-soluble (dimethyl sulfoxide-soluble) cigarette smoke particles (DSP) induces upregulation of contractile endothelin type B (ET(B)) receptors in rat cerebral arteries and if activation of mitogen activated protein kinase (MAPK) and nuclear factor-kappaB (NF-κB) mediate the upregulation of contractile endothelin receptors in the cerebral arteries. Rat middle cerebral arteries were isolated and organ cultured in serum free medium for 24 h in the presence of DSP with or without specific inhibitors: MEK specific (U0126), p38 specific (SB202190), JNK specific (SP600125), NF-κB specific (BMS-345541) or (IMD-0354), transcription inhibitor (actinomycin D), or translation blocker (cycloheximide). Contractile responses to the ET(B) receptor agonist sarafotoxin 6c were investigated by a sensitive myograph. The expression of the ET(B) receptors were studied at mRNA and protein levels using quantitative real time PCR and immunohistochemistry, respectively. Results show that organ culture per se induced transcriptional upregulation of contractile ET(B) receptors in the cerebral vascular smooth muscle cells. This upregulation was further increased at the translational level by addition of DSP to the organ culture, but this increase was not seen by addition of nicotine or water-soluble cigarette smoke particles to the organ culture. The increased upregulation of contractile ET(B) receptors by DSP was abrogated by U0126, SP600125, actinomycin D, and cycloheximide, suggesting that the underlying molecular mechanisms involved in this process include activation of MEK and JNK MAPK-mediated transcription and translation of new contractile ET(B) receptors. Thus, the MAPK-mediated upregulation of contractile ET(B) receptors in cerebral arteries might be a pharmacological target for the treatment of smoke-associated cerebral vascular disease like stroke.


Asunto(s)
Arteria Cerebral Media/metabolismo , Proteínas Quinasas Activadas por Mitógenos/metabolismo , Receptor de Endotelina B/biosíntesis , Fumar/metabolismo , Regulación hacia Arriba/fisiología , Vasoconstricción/fisiología , Animales , Dimetilsulfóxido/metabolismo , Dimetilsulfóxido/farmacología , Activación Enzimática/efectos de los fármacos , Activación Enzimática/fisiología , Metabolismo de los Lípidos/efectos de los fármacos , Metabolismo de los Lípidos/fisiología , Masculino , Arteria Cerebral Media/efectos de los fármacos , Técnicas de Cultivo de Órganos , Ratas , Ratas Sprague-Dawley , Solubilidad , Regulación hacia Arriba/efectos de los fármacos , Vasoconstricción/efectos de los fármacos
20.
ScientificWorldJournal ; 10: 2139-56, 2010 Nov 04.
Artículo en Inglés | MEDLINE | ID: mdl-21057728

RESUMEN

Tobacco use is one of the major risk factors of cardiovascular disease. The underlying molecular mechanisms that link cigarette smoke to cardiovascular disease remain unclear. The present study was designed to examine the effects of dimethyl sulfoxide (DMSO)-soluble smoke particles (DSPs) on human aortic smooth muscle cell (HASMC) cultures, and to explore the mitogen-activated protein kinase (MAPK)/extracellular signal-regulated protein kinase 1 and 2 (ERK1/2) and nuclear factor-kappaB (NF-κB) signal mechanisms involved. Serum-starved HASMCs were treated with DSPs for up to 48 h. DSPs promoted cell proliferation in a concentration-dependent manner from 0.05 to 0.2 µl/ml. Activation of ERK1/2 and NF-κB was seen after exposure to DSPs. This occurred in parallel with the increase in cell population, bromodeoxyuridine incorporation, and cyclinD1/cyclin-dependent kinase 4 expression. Blocking phosphorylation of ERK1/2 by MAPK inhibitors U0126 and PD98059, and inhibiting activation of NF-κB by IkappaB (IκB) kinase inhibitors wedelolactone or IMD-0354, abolished the DSP effects. However, either a p38 inhibitor (SB203580) or an inhibitor of lipopolysaccharide (polymyxin B), or nicotinic receptor blockers (mecamylamine and alpha-bungarotoxin), did not inhibit a DSP-induced increase in the cell population. DSPs increased the expression of intercellular adhesion molecule 1 and the release of interleukin-6 in HASMCs, both of which were inhibited by ERK1/2 or NF-κB pathway inhibitors. Furthermore, cell apoptosis and necrosis were found in serum-starved HASMCs. DSPs decreased cell death and increased B-cell leukemia/lymphoma 2 expression. Blocking phosphorylation of ERK1/2 or NF-κB attenuated DSP-induced cell death inhibition. Cigarette smoke particles stimulate HASMC proliferation and inhibit cell death. The intracellular signal mechanisms behind this involve activation of ERK1/2 and NF-κB pathways.


Asunto(s)
Proliferación Celular , Músculo Liso Vascular/metabolismo , Nicotiana/química , Transducción de Señal/fisiología , Humo , Apoptosis/efectos de los fármacos , Apoptosis/fisiología , Western Blotting , Línea Celular , Supervivencia Celular/efectos de los fármacos , Ciclina D1/metabolismo , Quinasa 4 Dependiente de la Ciclina/metabolismo , Relación Dosis-Respuesta a Droga , Humanos , Proteína Quinasa 1 Activada por Mitógenos/metabolismo , Proteína Quinasa 3 Activada por Mitógenos/metabolismo , Músculo Liso Vascular/citología , Músculo Liso Vascular/efectos de los fármacos , Miocitos del Músculo Liso/efectos de los fármacos , Miocitos del Músculo Liso/metabolismo , FN-kappa B/metabolismo , Fosforilación/efectos de los fármacos , Extractos Vegetales/química , Extractos Vegetales/farmacología , Proteínas Proto-Oncogénicas c-bcl-2/metabolismo , Transducción de Señal/efectos de los fármacos , Proteínas Quinasas p38 Activadas por Mitógenos/metabolismo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA